1. Home
  2. LPSN vs CING Comparison

LPSN vs CING Comparison

Compare LPSN & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LivePerson Inc.

LPSN

LivePerson Inc.

HOLD

Current Price

$3.28

Market Cap

47.0M

Sector

Technology

ML Signal

HOLD

CING

Cingulate Inc.

HOLD

Current Price

$5.37

Market Cap

40.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LPSN
CING
Founded
1995
2012
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.0M
40.5M
IPO Year
2000
2021

Fundamental Metrics

Financial Performance
Metric
LPSN
CING
Price
$3.28
$5.37
Analyst Decision
Hold
Strong Buy
Analyst Count
1
3
Target Price
N/A
$31.33
AVG Volume (30 Days)
211.4K
229.8K
Earning Date
03-04-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$257,660,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.94
$3.20
52 Week High
$23.55
$6.74

Technical Indicators

Market Signals
Indicator
LPSN
CING
Relative Strength Index (RSI) 35.40 62.79
Support Level $2.94 $4.83
Resistance Level $4.12 $6.74
Average True Range (ATR) 0.22 0.54
MACD -0.05 0.07
Stochastic Oscillator 29.11 45.16

Price Performance

Historical Comparison
LPSN
CING

About LPSN LivePerson Inc.

LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Company's enterprise-class digital customer conversation platform, is trusted by the world's top brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United Kingdom, Asia-Pacific, Latin America, and Europe.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.

Share on Social Networks: